A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
Long-term follow-up in such diseases as psoriasis and atopic dermatitis are reinforcing the empiric impression that a ‘super ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback